Gracell Biotechnologies (NASDAQ:GRCL – Get Rating) issued its quarterly earnings results on Monday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.14), Fidelity Earnings reports. During the same period in the prior year, the firm posted ($0.25) EPS.
GRCL opened at $3.43 on Tuesday. The company has a 50 day moving average of $2.37 and a 200 day moving average of $4.67. The company has a market cap of $237.56 million, a PE ratio of -4.13 and a beta of -1.27. Gracell Biotechnologies has a 12 month low of $1.68 and a 12 month high of $19.74. The company has a current ratio of 12.15, a quick ratio of 12.15 and a debt-to-equity ratio of 0.03.
A number of large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. boosted its holdings in Gracell Biotechnologies by 482.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 104,419 shares of the company’s stock valued at $243,000 after purchasing an additional 86,500 shares during the period. Vident Investment Advisory LLC boosted its holdings in Gracell Biotechnologies by 58.0% in the 1st quarter. Vident Investment Advisory LLC now owns 19,961 shares of the company’s stock valued at $47,000 after purchasing an additional 7,331 shares during the period. Invesco Ltd. boosted its holdings in Gracell Biotechnologies by 87.9% in the 1st quarter. Invesco Ltd. now owns 74,112 shares of the company’s stock valued at $173,000 after purchasing an additional 34,679 shares during the period. Renaissance Technologies LLC bought a new position in Gracell Biotechnologies in the 1st quarter valued at $55,000. Finally, BlackRock Inc. boosted its holdings in Gracell Biotechnologies by 18.6% in the 1st quarter. BlackRock Inc. now owns 924,631 shares of the company’s stock valued at $2,154,000 after purchasing an additional 144,940 shares during the period.
Gracell Biotechnologies Company Profile (Get Rating)
Gracell Biotechnologies Inc, a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on Gracell Biotechnologies (GRCL)
- VMWare Inc: Strong Revenues and Excellent Potential
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
Receive News & Ratings for Gracell Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gracell Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.